Callisto Pharmaceuticals
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
420 Lexington Ave Ste 1609, New York, Ne...Phone Number
(212) 297-0170Website
www.callistopharma.comRevenue
<$5 MillionIndustry
About Callisto Pharmaceuticals
Callisto Pharmaceuticals, Inc. is a publicly traded biotechnology company focused on the clinical development of cancer treatments, specifically Annamycin for relapsed leukemia and Atiprimod for relapsed multiple myeloma. The company is engaged in various clinical trials and has drugs in preclinical development for melanoma and gastrointestinal inflammation. Callisto operates through its subsidiaries, Callisto Research Labs, LLC and Synergy Pharmaceuticals Inc., and holds exclusive licenses for its key drugs. Its intended clients include patients suffering from specific types of cancer and healthcare providers involved in oncology.Explore more
Callisto Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Callisto Pharmaceuticals
Compare insights from companies similar to Callisto Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Callisto Pharmaceuticals Tech Stack
A closer look at the technologies used by Callisto Pharmaceuticals
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Callisto Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Callisto Pharmaceuticals, Inc. is a publicly traded biotechnology company focused on the clinical development of cancer treatments, specifically Annamycin for relapsed leukemia and Atiprimod for relapsed multiple myeloma. The company is engaged in various clinical trials and has drugs in preclinical development for melanoma and gastrointestinal inf... Read More
